QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
7.56B
Market cap7.56B
Price-Earnings ratio
19.40
Price-Earnings ratio19.40
Dividend yield
0.70%
Dividend yield0.70%
Average volume
2.19M
Average volume2.19M
High today
$37.80
High today$37.80
Low today
$36.54
Low today$36.54
Open price
$37.67
Open price$37.67
Volume
1.40M
Volume1.40M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$32.53
52 Week low$32.53

Stock Snapshot

The current QIAGEN(QGEN) stock price is $36.68, with a market capitalization of 7.56B. The stock trades at a price-to-earnings (P/E) ratio of 19.40 and offers a dividend yield of 70.1%.

As of 2026-06-05, QIAGEN(QGEN) stock has fluctuated between $36.54 and $37.80. The current price stands at $36.68, placing the stock +0.4% above today's low and -3.0% off the high.

The QIAGEN(QGEN)'s current trading volume is 1.4M, compared to an average daily volume of 2.19M.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $32.53.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $32.53.

QGEN News

Quartz 13h
QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com

...

QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com
Simply Wall St 15h
Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story?

In May 2026, QIAGEN N.V. announced research-use-only digital PCR assays for its QIAcuity platform to support Bundibugyo ebolavirus research, wastewater surveill...

Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story?
Simply Wall St 5d
Is It Time To Reconsider Qiagen After Recent Share Price Weakness?

Wondering if Qiagen's share price around US$36.59 reflects a fair deal or a mispricing that could matter for your returns? This article walks through what the v...

Is It Time To Reconsider Qiagen After Recent Share Price Weakness?

Analyst ratings

55%

of 20 ratings
Buy
45%
Hold
55%
Sell
0%

More QGEN News

Simply Wall St 6d
Qiagen’s New Ebola Assays Test Investor Views On Undervalued Shares

Qiagen launched new digital PCR assays for Bundibugyo ebolavirus surveillance, expanding its infectious disease research tools. The assays are research use onl...

Qiagen’s New Ebola Assays Test Investor Views On Undervalued Shares

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.